IMKELDI

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
IMKELDI
Generic name
IMATINIB ORAL
Manufacturer
Shorla Oncology Inc.,
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
26658bb7-9ba1-a10e-e063-6394a90a172e
SPL ID
5e6aee3d-613f-e4bc-e063-6294a90a5dae
Version
5
Effective date
2026-10-22
Source export date
2026-11-13
Source partition
8
Source file
https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/5b373538593b900129b6789b4289137dca62e689b6d06cab0e8e33844e7e2588/drug-label-0008-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:55:19
Harmonized routes table
Harmonized routes
ORAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Fluid Retention and Edema: Edema and severe fluid retention have occurred. Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. ( 5.1 , 6.1 ) Hematologic Toxicity: Cytopenias, particularly anemia, neutropenia, and thrombocytopenia, have occurred. Manage with dose reduction, dose interruption, or discontinuation of treatment. Perform complete blood counts weekly for the first month, biweekly for the second month, and periodically thereafter. ( 5.2 ) Congestive Heart Failure and Left Ventricular Dysfunction: Severe congestive heart failure and left ventricular dysfunction have been reported, particularly in patients with comorbidities and risk factors. Monitor and treat patients with cardiac disease or risk factors for cardiac failure. ( 5.3 ) Hepatotoxicity: Severe hepatotoxicity, including fatalities may occur. Assess liver function before initiation of treatment and monthly thereafter or as clinically indicated. Monitor liver function when combined with chemotherapy known to be associated with liver dysfunction. ( 5.4 ) Hemorrhage: Grade 3/4 hemorrhage has been reported in clinical studies in patients with newly diagnosed CML and with GIST. GI tumor sites may be the source of GI bleeds in GIST. ( 5.5 ) Gastrointestinal Disorders: Gastrointestinal (GI) perforations, some fatal, have been reported. ( 5.6 ) Hypereosinophilic Cardiac Toxicity: Cardiogenic shock/left ventricular dysfunction has been associated with the initiation of IMKELDI in patients with conditions associated with high eosinophil levels (e.g., HES, MDS/MPD, and ASM). ( 5.7 ) Dermatologic Toxicities: Bullous dermatologic reactions (e.g., erythema multiforme and Stevens-Johnson syndrome) have been reported with the use of IMKELDI. ( 5.8 ) Hypothyroidism: Hypothyroidism has been reported in thyroidectomy patients undergoing levothyroxine replacement. Closely monitor TSH levels in such patients. ( 5.9 ) Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus, and to use effective contraception. ( 5.10 , 8.1 ) Growth Retardation in Children and Adolescents: Growth retardation occurring in children and pre-adolescents receiving IMKELDI has been reported. Close monitoring of growth in children under IMKELDI treatment is recommended. ( 5.11 , 6.2 ) Tumor Lysis Syndrome: Close monitoring is recommended. ( 5.12 ) Impairments Related to Driving and Using Machinery: Motor vehicle accidents have been reported in patients receiving imatinib. Caution patients about driving a car or operating machinery. ( 5.13 ) Renal Toxicity: A decline in renal function may occur in patients receiving IMKELDI. Evaluate renal function at baseline and during therapy, with attention to risk factors for renal dysfunction. ( 5.14 ) Measuring Device: Advise patients to measure IMKELDI with an accurate milliliter measuring device. Inform patients that a household teaspoon is not an accurate measuring device and could lead to overdosage, which can result in serious adverse reactions. Advise patients to ask their pharmacist to recommend an appropriate press-in bottle adapter and oral dispensing syringe and for instructions for measuring the correct dose. ( 5.15 ) 5.1 Fluid Retention and Edema Imatinib can cause edema and occasionally serious fluid retention [see Adverse Reactions (6.1) ] . Weigh and monitor patients regularly for signs and symptoms of fluid retention. Investigate unexpected rapid weight gain carefully and provide appropriate treatment. The probability of edema was increased with higher imatinib dose and age greater than 65 years in the CML studies. Severe superficial edema was reported in 1.5% of newly diagnosed CML patients taking imatinib, and in 2% to 6% of other adult CML patients taking imatinib. In addition, other severe fluid retention (e.g., pleural effusion, pericardial effusion, pulmonary edema, and ascites) reactions were reported in 1.3% of newly diagnosed CML patients taking imatinib, and in 2% to 6% of other adult CML patients taking imatinib. Severe fluid retention was reported in 9% to 13.1% of patients taking imatinib for GIST [see Adverse Reactions (6.1) ] . In a randomized trial in patients with newly diagnosed Ph+ CML in chronic phase comparing imatinib and nilotinib, severe (Grade 3 or 4) fluid retention occurred in 2.5% of patients receiving imatinib and in 3.9% of patients receiving nilotinib 300 mg twice daily. Effusions (including pleural effusion, pericardial effusion, ascites) or pulmonary edema were observed in 2.1% (none were Grade 3 or 4) of patients in the imatinib arm and 2.2% (0.7% Grade 3 or 4) of patients in the nilotinib 300 mg twice daily arm. 5.2 Hematologic Toxicity Treatment with imatinib can cause anemia, neutropenia, and thrombocytopenia. Perform complete blood counts weekly for the first month, biweekly for the second month, and periodically thereafter as clinically indicated (for example, every 2 to 3 months). In CML, the occurrence of these cytopenias is dependent on the stage of disease and is more frequent in patients with accelerated phase CML or blast crisis than in patients with chronic phase CML. In pediatric CML patients the most frequent toxicities observed were Grade 3 or 4 cytopenias, including neutropenia, thrombocytopenia, and anemia. These generally occur within the first several months of therapy [see Dosage and Administration (2.14) ]. 5.3 Congestive Heart Failure and Left Ventricular Dysfunction Congestive heart failure and left ventricular dysfunction have been reported in patients taking imatinib. Cardiac adverse reactions were more frequent in patients with advanced age or co-morbidities, including previous medical history of cardiac disease. In an international randomized Phase 3 study in 1106 patients with newly diagnosed Ph+ CML in chronic phase, severe cardiac failure and left ventricular dysfunction were observed in 0.7% of patients taking imatinib compared to 0.9% of patients taking IFN + Ara-C. In another randomized trial with newly diagnosed Ph+ CML patients in chronic phase that compared imatinib and nilotinib, cardiac failure was observed in 1.1% of patients in the imatinib arm and 2.2% of patients in the nilotinib 300 mg twice daily arm and severe (Grade 3 or 4) cardiac failure occurred in 0.7% of patients in each group. Carefully monitor patients with cardiac disease or risk factors for cardiac or history of renal failure. Evaluate and treat any patient with signs or symptoms consistent with cardiac or renal failure. 5.4 Hepatotoxicity Hepatotoxicity, occasionally severe, may occur with Imkeldi [see Adverse Reactions (6.1) ]. Cases of fatal liver failure and severe liver injury requiring liver transplants have been reported with both short-term and long-term use of imatinib. Monitor liver function (transaminases, bilirubin, and alkaline phosphatase) before initiation of treatment and monthly, or as clinically indicated. Manage laboratory abnormalities with Imkeldi interruption and/or dose reduction [see Dosage and Administration (2.13) ]. When imatinib is combined with chemotherapy, liver toxicity in the form of transaminase elevation and hyperbilirubinemia has been observed. Additionally, there have been reports of acute liver failure. Monitoring of hepatic function is recommended. 5.5 Hemorrhage In a trial of imatinib versus IFN+Ara-C in patients with the newly diagnosed CML, 1.8% of patients had Grade 3/4 hemorrhage. In the Phase 3 unresectable or metastatic GIST studies, 211 patients (12.9%) reported Grade 3/4 hemorrhage at any site. In the Phase 2 unresectable or metastatic GIST study, 7 patients (5%) had a total of 8 CTC Grade 3/4 hemorrhages; gastrointestinal (GI) (3 patients), intra-tumoral (3 patients) or both (1 patient). Gastrointestinal tumor sites may have been the source of GI hemorrhages. In a randomized trial in patients with newly diagnosed Ph+ CML in chronic phase comparing imatinib and nilotinib, GI hemorrhage occurred in 1.4% of patients in the imatinib arm, and in 2.9% of patients in the nilotinib 300 mg twice daily arm. None of these events were Grade 3 or 4 in the imatinib arm; 0.7% were Grade 3 or 4 in the nilotinib 300 mg twice daily arm. In addition, gastric antral vascular ectasia has been reported in postmarketing experience. 5.6 Gastrointestinal Disorders Imatinib can cause GI irritation. Imkeldi should be taken with food and a large glass of water to minimize this problem. There have been rare reports, including fatalities, of GI perforation. 5.7 Hypereosinophilic Cardiac Toxicity In patients with hypereosinophilic syndrome with occult infiltration of HES cells within the myocardium, cases of cardiogenic shock/left ventricular dysfunction have been associated with HES cell degranulation upon the initiation of Imkeldi therapy. The condition was reported to be reversible with the administration of systemic steroids, circulatory support measures and temporarily withholding Imkeldi. Myelodysplastic/myeloproliferative disease and systemic mastocytosis may be associated with high eosinophil levels. Consider performing an echocardiogram and determining serum troponin in patients with HES/CEL, and in patients with MDS/MPD or ASM associated with high eosinophil levels. If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Imkeldi at the initiation of therapy. 5.8 Dermatologic Toxicities Bullous dermatologic reactions, including erythema multiforme and Stevens-Johnson syndrome, have been reported with use of imatinib. In some cases of bullous dermatologic reactions, including erythema multiforme and Stevens-Johnson syndrome reported during postmarketing surveillance, a recurrent dermatologic reaction was observed upon rechallenge. Several foreign postmarketing reports have described cases in which patients tolerated the reintroduction of imatinib therapy after resolution or improvement of the bullous reaction. In these instances, imatinib was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. 5.9 Hypothyroidism Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with imatinib. Monitor TSH levels in such patients. 5.10 Embryo-Fetal Toxicity Imkeldi can cause fetal harm when administered to a pregnant woman. Imatinib mesylate was teratogenic in rats when administered during organogenesis at doses approximately equal to the maximum human dose of 800 mg/day based on body surface area (BSA). Significant post-implantation loss was seen in female rats administered imatinib mesylate at doses approximately one-half the maximum human dose of 800 mg/day based on BSA. Advise females of reproductive potential to use effective contraception (methods that result in less than 1% pregnancy rates) when using Imkeldi and for 14 days after stopping Imkeldi. Advise pregnant women of the potential risk to a fetus [see Use in Specific Populations (8.1) ] . 5.11 Growth Retardation in Children and Adolescents Growth retardation has been reported in children and pre-adolescents receiving imatinib. The long-term effects of prolonged treatment with Imkeldi on growth in children are unknown. Therefore, monitor growth in children under Imkeldi treatment [see Adverse Reactions (6.1) ]. 5.12 Tumor Lysis Syndrome Cases of Tumor Lysis Syndrome (TLS), including fatal cases, have been reported in patients with CML, GIST, ALL, and eosinophilic leukemia receiving imatinib. The patients at risk of TLS are those with tumors having a high proliferative rate or high tumor burden prior to treatment. Monitor these patients closely and take appropriate precautions. Due to possible occurrence of TLS, correct clinically significant dehydration and treat high uric acid levels prior to initiation of Imkeldi. 5.13 Impairments Related to Driving and Using Machinery Motor vehicle accidents have been reported in patients receiving imatinib. Advise patients that they may experience side effects, such as dizziness, blurred vision, or somnolence during treatment with Imkeldi. Recommend caution when driving a car or operating machinery. 5.14 Renal Toxicity A decline in renal function may occur in patients receiving Imkeldi. Median estimated glomerular filtration rate (eGFR) values in patients on imatinib 400 mg daily for newly-diagnosed CML (four randomized trials) and malignant GIST (one single-arm trial) declined from a baseline value of 85 mL/min/1.73 m 2 (N = 1190) to 75 mL/min/1.73 m 2 at 12 months (N = 1082) and 69 mL/min/1.73 m 2 at 60 months (N = 549). Evaluate renal function prior to initiating Imkeldi and monitor during therapy, with attention to risk factors for renal dysfunction, such as preexisting renal impairment, diabetes mellitus, hypertension, and congestive heart failure. 5.15 Measuring Device Advise patients to measure Imkeldi with an accurate milliliter measuring device. Inform patients that a household teaspoon is not an accurate measuring device and could lead to overdosage, which can result in serious adverse reactions. Advise patients to ask their pharmacist to recommend an appropriate press-in bottle adapter and oral dispensing syringe and for instructions for measuring the correct dose [see Instructions for Use ].

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 2 of 4 · 15 matching rows.

adverse reactions table

<table width="100%"> <caption> Table 5: Laboratory Abnormalities in Newly Diagnosed CML Clinical Trial (Imatinib Versus IFN+Ara-C)</caption> <tbody> <tr> <td/> <td colspan="2" align="center"> <paragraph> <content styleCode="bold"> Imatinib</content> </paragraph> <paragraph> <content styleCode="bold">N = 551 </content> </paragraph> </td> <td colspan="2" align="center"> <paragraph> <content styleCode="bold"> IFN+Ara-C</content> </paragraph> <paragraph> <content styleCode="bold">N = 533 </content> </paragraph> </td> </tr> <tr> <td/> <td colspan="2" align="center"> <content styleCode="bold"> % </content> </td> <td colspan="2" align="center"> <content styleCode="bold"> % </content> </td> </tr> <tr> <td> <content styleCode="bold"> CTC Grades</content> </td> <td align="center"> <content styleCode="bold"> Grade 3</content> </td> <td align="center"> <content styleCode="bold">Grade 4</content> </td> <td align="center"> <content styleCode="bold"> Grade 3</content> </td> <td align="center"> <content styleCode="bold"> Grade 4</content> </td> </tr> <tr> <td align="left" styleCode="Toprule"> <content styleCode="bold"> Hematology parameters*</content> </td> <td align="center" styleCode="Toprule"/> <td align="center" styleCode="Toprule"/> <td align="center" styleCode="Toprule"/> <td align="center" styleCode="Toprule"/> </tr> <tr> <td> - Neutropenia*</td> <td align="center"> 13.1</td> <td align="center"> 3.6</td> <td align="center"> 20.8</td> <td align="center"> 4.5</td> </tr> <tr> <td> - Thrombocytopenia*</td> <td align="center"> 8.5</td> <td align="center"> 0.4</td> <td align="center"> 15.9</td> <td align="center"> 0.6</td> </tr> <tr> <td> - Anemia</td> <td align="center"> 3.3</td> <td align="center"> 1.1</td> <td align="center"> 4.1</td> <td align="center"> 0.2</td> </tr> <tr> <td> <content styleCode="bold"> Biochemistry parameters</content> </td> <td/> <td/> <td/> <td/> </tr> <tr> <td> - Elevated creatinine</td> <td align="center"> 0</td> <td align="center"> 0</td> <td align="center"> 0.4</td> <td align="center"> 0</td> </tr> <tr> <td> - Elevated bilirubin</td> <td align="center"> 0.9</td> <td align="center"> 0.2</td> <td align="center"> 0.2</td> <td align="center"> 0</td> </tr> <tr> <td> - Elevated alkaline phosphatase</td> <td align="center"> 0.2</td> <td align="center"> 0</td> <td align="center"> 0.8</td> <td align="center"> 0</td> </tr> <tr> <td align="left" styleCode="Botrule"> - Elevated SGOT (AST)/SGPT (ALT)</td> <td align="center" styleCode="Botrule"> 4.7</td> <td align="center" styleCode="Botrule"> 0.5</td> <td align="center" styleCode="Botrule"> 7.1</td> <td align="center" styleCode="Botrule"> 0.4</td> </tr> <tr> <td colspan="5"> <paragraph>Abbreviations: CML, chronic myeloid leukemia; IFN, Interferon-alpha; SGOT, serum glutamic-oxaloacetic transaminase is now referred to as aspartate aminotransferase (AST); SGPT, serum glutamic-pyruvic transaminase is now referred to as alanine aminotransferase (ALT).</paragraph> <paragraph>*p less than 0.001 (difference in Grade 3 plus 4 abnormalities between the two treatment groups).</paragraph> </td> </tr> </tbody> </table>

adverse reactions table

<table width="100%"> <caption> Table 6: Percent Incidence of Clinically Relevant Grade 3/4* Laboratory Abnormalities in the Newly Diagnosed CML Clinical Trial (Imatinib Versus Nilotinib)</caption> <tbody> <tr> <td/> <td align="center"> <content styleCode="bold">Imatinib 400 mg</content> <content styleCode="bold">once daily</content> </td> <td align="center"> <content styleCode="bold"> Nilotinib 300 mg</content> <content styleCode="bold">twice daily</content> </td> </tr> <tr> <td/> <td align="center"> <content styleCode="bold"> N = 280</content> </td> <td align="center"> <content styleCode="bold"> N = 279</content> </td> </tr> <tr> <td/> <td align="center"> <content styleCode="bold"> (%)</content> </td> <td align="center"> <content styleCode="bold"> (%)</content> </td> </tr> <tr> <td align="left" styleCode="Toprule"> <content styleCode="bold"> Hematologic parameters</content> </td> <td align="center" styleCode="Toprule"/> <td align="center" styleCode="Toprule"/> </tr> <tr> <td> Thrombocytopenia</td> <td align="center"> 9</td> <td align="center"> 10</td> </tr> <tr> <td> Neutropenia</td> <td align="center"> 22</td> <td align="center"> 12</td> </tr> <tr> <td> Anemia</td> <td align="center"> 6</td> <td align="center"> 4</td> </tr> <tr> <td> <content styleCode="bold"> Biochemistry parameters</content> </td> <td/> <td/> </tr> <tr> <td> Elevated lipase</td> <td align="center"> 4</td> <td align="center"> 9</td> </tr> <tr> <td> Hyperglycemia</td> <td align="center"> &lt; 1</td> <td align="center"> 7</td> </tr> <tr> <td> Hypophosphatemia</td> <td align="center"> 10</td> <td align="center"> 8</td> </tr> <tr> <td> Elevated bilirubin (total)</td> <td align="center"> &lt; 1</td> <td align="center"> 4</td> </tr> <tr> <td> Elevated SGPT (ALT)</td> <td align="center"> 3</td> <td align="center"> 4</td> </tr> <tr> <td> Hyperkalemia</td> <td align="center"> 1</td> <td align="center"> 2</td> </tr> <tr> <td> Hyponatremia</td> <td align="center"> &lt; 1</td> <td align="center"> 1</td> </tr> <tr> <td> Hypokalemia</td> <td align="center"> 2</td> <td align="center"> &lt; 1</td> </tr> <tr> <td> Elevated SGOT (AST)</td> <td align="center"> 1</td> <td align="center"> 1</td> </tr> <tr> <td> Decreased albumin</td> <td align="center"> &lt; 1</td> <td align="center"> 0</td> </tr> <tr> <td> Hypocalcemia</td> <td align="center"> &lt; 1</td> <td align="center"> &lt; 1</td> </tr> <tr> <td> Elevated alkaline phosphatase</td> <td align="center"> &lt; 1</td> <td align="center"> 0</td> </tr> <tr> <td align="left" styleCode="Botrule"> Elevated creatinine</td> <td align="center" styleCode="Botrule"> &lt; 1</td> <td align="center" styleCode="Botrule"> 0</td> </tr> <tr> <td colspan="3"> <paragraph>Abbreviations: CML, chronic myeloid leukemia; SGOT, serum glutamic-oxaloacetic transaminase is now referred to as aspartate aminotransferase (AST); SGPT, serum glutamic-pyruvic transaminase is now referred to as alanine aminotransferase (ALT).</paragraph> <paragraph>*NCI Common Terminology Criteria for Adverse Events, version 3.0.</paragraph> </td> </tr> </tbody> </table>

adverse reactions table

<table width="100%"> <caption> Table 7: Laboratory Abnormalities in Other CML Clinical Trials</caption> <tbody> <tr> <td/> <td colspan="2" align="center"> <content styleCode="bold"> Myeloid blast crisis</content> </td> <td colspan="2" align="center"> <content styleCode="bold"> Accelerated phase</content> </td> <td colspan="2" align="center"> <content styleCode="bold"> Chronic phase, IFN failure</content> </td> </tr> <tr> <td/> <td colspan="2" align="center"> <content styleCode="bold"> (n = 260)</content> </td> <td colspan="2" align="center"> <content styleCode="bold"> (n = 235)</content> </td> <td colspan="2" align="center"> <content styleCode="bold"> (n = 532)</content> </td> </tr> <tr> <td/> <td colspan="2" align="center"> <content styleCode="bold"> 600 mg n = 223</content> </td> <td colspan="2" align="center"> <content styleCode="bold"> 600 mg n = 158</content> </td> <td colspan="2"/> </tr> <tr> <td/> <td colspan="2" align="center"> <content styleCode="bold"> 400 mg n = 37</content> </td> <td colspan="2" align="center"> <content styleCode="bold"> 400 mg n = 77</content> </td> <td colspan="2" align="center"> <content styleCode="bold"> 400 mg</content> </td> </tr> <tr> <td/> <td colspan="2" align="center"> <content styleCode="bold"> %</content> </td> <td colspan="2" align="center"> <content styleCode="bold"> %</content> </td> <td colspan="2" align="center"> <content styleCode="bold"> %</content> </td> </tr> <tr> <td> <content styleCode="bold"> CTC Grades </content> <sup>(1)</sup> </td> <td align="center"> <content styleCode="bold"> Grade 3</content> </td> <td align="center"> <content styleCode="bold"> Grade 4</content> </td> <td align="center"> <content styleCode="bold"> Grade 3</content> </td> <td align="center"> <content styleCode="bold"> Grade 4</content> </td> <td align="center"> <content styleCode="bold"> Grade 3</content> </td> <td align="center"> <content styleCode="bold"> Grade 4</content> </td> </tr> <tr> <td align="left" styleCode="Toprule"> <content styleCode="bold"> Hematology parameters</content> </td> <td align="center" styleCode="Toprule"/> <td align="center" styleCode="Toprule"/> <td align="center" styleCode="Toprule"/> <td align="center" styleCode="Toprule"/> <td align="center" styleCode="Toprule"/> <td align="center" styleCode="Toprule"/> </tr> <tr> <td> - Neutropenia</td> <td align="center"> 16</td> <td align="center"> 48</td> <td align="center"> 23</td> <td align="center"> 36</td> <td align="center"> 27</td> <td align="center"> 9</td> </tr> <tr> <td> - Thrombocytopenia</td> <td align="center"> 30</td> <td align="center"> 33</td> <td align="center"> 31</td> <td align="center"> 13</td> <td align="center"> 21</td> <td align="center"> &lt; 1</td> </tr> <tr> <td> - Anemia</td> <td align="center"> 42</td> <td align="center"> 11</td> <td align="center"> 34</td> <td align="center"> 7</td> <td align="center"> 6</td> <td align="center"> 1</td> </tr> <tr> <td> <content styleCode="bold">Biochemistry parameters</content> </td> <td/> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> - Elevated creatinine</td> <td align="center"> 1.5</td> <td align="center"> 0</td> <td align="center"> 1.3</td> <td align="center"> 0</td> <td align="center"> 0.2</td> <td align="center"> 0</td> </tr> <tr> <td> - Elevated bilirubin</td> <td align="center"> 3.8</td> <td align="center"> 0</td> <td align="center"> 2.1</td> <td align="center"> 0</td> <td align="center"> 0.6</td> <td align="center"> 0</td> </tr> <tr> <td> - Elevated alkaline phosphatase</td> <td align="center"> 4.6</td> <td align="center"> 0</td> <td align="center"> 5.5</td> <td align="center"> 0.4</td> <td align="center"> 0.2</td> <td align="center"> 0</td> </tr> <tr> <td> - Elevated SGOT (AST)</td> <td align="center"> 1.9</td> <td align="center"> 0</td> <td align="center"> 3.0</td> <td align="center"> 0</td> <td align="center"> 2.3</td> <td align="center"> 0</td> </tr> <tr> <td align="left" styleCode="Botrule"> - Elevated SGPT (ALT)</td> <td align="center" styleCode="Botrule"> 2.3</td> <td align="center" styleCode="Botrule"> 0.4</td> <td align="center" styleCode="Botrule"> 4.3</td> <td align="center" styleCode="Botrule"> 0 </td> <td align="center" styleCode="Botrule"> 2.1</td> <td align="center" styleCode="Botrule"> 0</td> </tr> <tr> <td colspan="7"> <paragraph>Abbreviations: CML, chronic myeloid leukemia; CTC, common terminology criteria; IFN, Interferon-alpha; SGOT, serum glutamic-oxaloacetic transaminase is now referred to as aspartate aminotransferase (AST); SGPT, serum glutamic-pyruvic transaminase is now referred to as alanine aminotransferase (ALT).</paragraph> <paragraph> <sup>(1)</sup>CTC Grades: neutropenia (Grade 3 greater than or equal to 0.5&#x2013;1.0 x 10 <sup>9</sup>/L, Grade 4 less than 0.5 x 10 <sup>9</sup>/L), thrombocytopenia (Grade 3 greater than or equal to 10&#x2013;50 x 10 <sup>9</sup>/L, Grade 4 less than 10 x 10 <sup>9</sup>/L), anemia (hemoglobin greater than or equal to 65&#x2013;80 g/L, Grade 4 less than 65 g/L), elevated creatinine (Grade 3 greater than 3&#x2013;6 x upper limit normal range [ULN], Grade 4 greater than 6 x ULN), elevated bilirubin (Grade 3 greater than 3&#x2013;10 x ULN, Grade 4 greater than 10 x ULN), elevated alkaline phosphatase (Grade 3 greater than 5&#x2013;20 x ULN, Grade 4 greater than 20 x ULN), elevated SGOT or SGPT (Grade 3 greater than 5&#x2013;20 x ULN, Grade 4 greater than 20 x ULN). </paragraph> </td> </tr> </tbody> </table>

adverse reactions table

<table width="100%"> <caption> Table 8: Adverse Reactions Reported More Frequently in Patients Treated With Study Drug (Greater Than 5%) or in Cycles With Study Drug (Greater Than 1%)</caption> <tbody> <tr> <td> <content styleCode="bold"> Adverse event</content> </td> <td align="center"> <paragraph> <content styleCode="bold"> Per patient incidence Ph+ ALL</content> <content styleCode="bold">with Imatinib</content> </paragraph> <paragraph> <content styleCode="bold">N = 92</content> <content styleCode="bold">n (%)</content> </paragraph> </td> <td align="center"> <paragraph> <content styleCode="bold"> Per patient incidence Ph- ALL</content> <content styleCode="bold">no Imatinib</content> </paragraph> <paragraph> <content styleCode="bold">N = 65</content> </paragraph> <paragraph> <content styleCode="bold">n (%)</content> </paragraph> </td> <td align="center"> <paragraph> <content styleCode="bold"> Per patient per cycle incidence</content> <content styleCode="bold">with Imatinib*</content> </paragraph> <paragraph> <content styleCode="bold">N = 778</content> <content styleCode="bold">n (%)</content> </paragraph> </td> <td align="center"> <paragraph> <content styleCode="bold">Per patient per cycle incidence</content> <content styleCode="bold">no Imatinib**</content> </paragraph> <paragraph> <content styleCode="bold">N = 647</content> <content styleCode="bold">n (%) </content> </paragraph> </td> </tr> <tr> <td> <content styleCode="bold"> Grade 3 and 4 adverse events</content> </td> <td/> <td/> <td/> <td/> </tr> <tr> <td align="left" styleCode="Toprule"> Nausea and/or vomiting</td> <td align="center" styleCode="Toprule"> 15 (16)</td> <td align="center" styleCode="Toprule"> 6 (9)</td> <td align="center" styleCode="Toprule"> 28 (4)</td> <td align="center" styleCode="Toprule"> 8 (1)</td> </tr> <tr> <td> Hypokalemia</td> <td align="center"> 31 (34)</td> <td align="center"> 16 (25)</td> <td align="center"> 72 (9)</td> <td align="center"> 32 (5)</td> </tr> <tr> <td> Pneumonitis</td> <td align="center"> 7 (8)</td> <td align="center"> 1 (1)</td> <td align="center"> 7 (1)</td> <td align="center"> 1 (&lt; 1)</td> </tr> <tr> <td> Pleural effusion</td> <td align="center"> 6 (7)</td> <td align="center"> 0</td> <td align="center"> 6 (1)</td> <td align="center"> 0</td> </tr> <tr> <td> Abdominal pain</td> <td align="center"> 8 (9)</td> <td align="center"> 2 (3)</td> <td align="center">9 (1)</td> <td align="center"> 3 (&lt; 1)</td> </tr> <tr> <td> Anorexia</td> <td align="center"> 10 (11)</td> <td align="center"> 3 (5)</td> <td align="center"> 19 (2)</td> <td align="center"> 4 (1)</td> </tr> <tr> <td> Hemorrhage</td> <td align="center"> 11 (12)</td> <td align="center"> 4 (6)</td> <td align="center"> 17 (2)</td> <td align="center"> 8 (1)</td> </tr> <tr> <td> Hypoxia</td> <td align="center"> 8 (9)</td> <td align="center"> 2 (3)</td> <td align="center"> 12 (2)</td> <td align="center"> 2 (&lt; 1)</td> </tr> <tr> <td> Myalgia</td> <td align="center"> 5 (5)</td> <td align="center"> 0</td> <td align="center"> 4 (1)</td> <td align="center"> 1 (&lt; 1)</td> </tr> <tr> <td> Stomatitis</td> <td align="center"> 15 (16)</td> <td align="center"> 8 (12)</td> <td align="center"> 22 (3)</td> <td align="center"> 14 (2)</td> </tr> <tr> <td> Diarrhea</td> <td align="center"> 8 (9)</td> <td align="center"> 3 (5)</td> <td align="center"> 12 (2)</td> <td align="center"> 3 (&lt; 1)</td> </tr> <tr> <td> Rash/Skin disorder</td> <td align="center"> 4 (4)</td> <td align="center"> 0</td> <td align="center"> 5 (1)</td> <td align="center"> 0</td> </tr> <tr> <td> Infection</td> <td align="center"> 49 (53)</td> <td align="center"> 32 (49)</td> <td align="center"> 131 (17)</td> <td align="center"> 92 (14)</td> </tr> <tr> <td> Hepatic (transaminase and/or bilirubin)</td> <td align="center"> 52 (57)</td> <td align="center"> 38 (58)</td> <td align="center"> 172 (22)</td> <td align="center"> 113 (17)</td> </tr> <tr> <td> Hypotension</td> <td align="center"> 10 (11)</td> <td align="center"> 5 (8)</td> <td align="center"> 16 (2)</td> <td align="center"> 6 (1)</td> </tr> <tr> <td> <content styleCode="bold"> Myelosuppression</content> </td> <td/> <td/> <td/> <td/> </tr> <tr> <td> Neutropenia (&lt; 750/mcL)</td> <td align="center"> 92 (100)</td> <td align="center"> 63 (97)</td> <td align="center"> 556 (71)</td> <td align="center"> 218 (34)</td> </tr> <tr> <td align="left" styleCode="Botrule"> Thrombocytopenia (&lt; 75,000/mcL)</td> <td align="center" styleCode="Botrule"> 90 (92)</td> <td align="center" styleCode="Botrule"> 63 (97)</td> <td align="center" styleCode="Botrule"> 431 (55)</td> <td align="center" styleCode="Botrule"> 329 (51)</td> </tr> <tr> <td colspan="5"> <paragraph>Abbreviations: Ph+ ALL, Philadelphia chromosome positive acute lymphoblastic leukemia; Ph- ALL, Philadelphia chromosome negative acute lymphoblastic leukemia.</paragraph> <paragraph>*Defined as the frequency of adverse events (AEs) per patient per treatment cycles that included imatinib (includes patients with Ph+ ALL that received cycles with imatinib). **Defined as the frequency of AEs per patient per treatment cycles that did not include imatinib (includes patients with Ph+ ALL that received cycles without imatinib as well as all patients with Ph- ALL who did not receive imatinib in any treatment cycle). </paragraph> </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.